ReviewBundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz2020
Dengue vaccine development: status and future.
Review in Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 93 citations in OpenAlex.
- Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America.The Journal of infectious diseases · 2025Trial
- Antibodies Produced in Response to a Live-Attenuated Dengue Vaccine Are Functional in Activating the Complement System.The Journal of infectious diseases · 2023Trial
- Integrating the Wei-Qi-Ying-Blood Theory with Modern Pathophysiology: A Multitarget Translational Framework for Dengue Management.International journal of general medicine · 2026Review
- Review
- Multivariate forecasting of dengue infection in Bangladesh: evaluating the influence of data downscaling on machine learning predictive accuracy.BMC infectious diseases · 2025Article
- The Role of Digital Opinion Leaders in Dengue Prevention Through Health Promotion and Public Health Collaboration: Qualitative Semistructured Interview Study.Journal of medical Internet research · 2025Article
- Knowledge, attitude, and practice regarding dengue vaccine: a baseline study of community members and health providers in Indonesia.Clinical and experimental pediatrics · 2025Article
- Reconciling heterogeneous dengue virus infection risk estimates from different study designs.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Overcoming dengue vaccine challenges through next-generation virus-like particle immunization strategies.Frontiers in cellular and infection microbiology · 2025Review
- Recommendations for dengue vaccine implementation in the elderly population.Therapeutic advances in vaccines and immunotherapy · 2025Review
- i-DENV: development of QSAR based regression models for predicting inhibitors targeting non-structural (NS) proteins of dengue virus.Frontiers in pharmacology · 2025Article
- The pre- and post-COVID-19 pandemic dengue fever patterns in southeastern coastal China in 2019 and 2024: molecular evolution and strain replacement.Frontiers in microbiology · 2025Article
- Forecasting dengue in Bangladesh using meteorological variables with a novel feature selection approach.Scientific reports · 2024Article
- Reconciling heterogeneous dengue virus infection risk estimates from different study designs.medRxiv : the preprint server for health sciences · 2024Article
- Infectious eye disease in the 21st century-an overview.Eye (London, England) · 2024Review
- Approaches of dengue control: vaccine strategies and future aspects.Frontiers in immunology · 2024Review
- Effects of the source of information and knowledge of dengue fever on the mosquito control behavior of residents of border areas of Yunnan, China.Parasites & vectors · 2023Article
- Exploring the inhibitory potential ofRSC advances · 2023Article
- Article
- Glycan masking in vaccine design: Targets, immunogens and applications.Frontiers in immunology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue, the most common arbovirus, represents an increasingly significant cause of morbidity worldwide, including in travelers. After decades of research, the first dengue vaccine was licensed in 2015: CYD-TDV, a tetravalent live attenuated vaccine with a yellow fever vaccine backbone. Recent analyses have shown that vaccine performance is dependent on serostatus. In those who have had a previous dengue infection, i.e., who are seropositive, the efficacy is high and the vaccine is safe. However, in seronegative vaccinees, approximately 3 years after vaccination the vaccine increases the risk of developing severe dengue when the individual experiences a natural dengue infection.The World Health Organization recommends that this vaccine be administered only to seropositive individuals. Current efforts are underway to develop rapid diagnostic tests to facilitate prevaccination screening. Two second-generation dengue vaccine candidates, both also live attenuated recombinant vaccines in late-stage development, may not present the same limitations because of differences in the backbone used, but results of phase 3 trials need to be available before firm conclusions can be drawn.Dengue is increasingly frequent in travelers, but the only licensed dengue vaccine to date can be used only in seropositive individuals. However, the vast majority of travelers are seronegative. Furthermore, the primary series of three doses given 6 months apart renders this vaccine difficult in the travel medicine context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.